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Abstract: Using tissue microarrays assembling 465 nevi, primary
melanomas and metastases, we investigated whether expression of
methylthioadenosine phosphorylase (MTAP), a recently suggested
biomarker of malignant melanoma, has prognostic significance
and may predict responsiveness to adjuvant interferon therapy in
patients with melanoma. Because of its association with MTAP
activity and interferon signalling pathways, signal transducer and
activator of transcription 1 (STAT1) immunohistochemistry was
analysed, too. MTAP expression was significantly reduced in
melanomas and metastases compared with nevi (P < 0.001);
STAT1 expression significantly increased. In melanomas, loss of
MTAP expression was significantly related to Clark level
(P < 0.05) and tumor thickness (P < 0.01); whereas STAT1
immunoreactivity was significantly related to gender (p < 0.05)
and tumor thickness (P < 0.05). Interestingly, subgroup analysis
of patients with a tumor thickness of 1.5–4.0 mm revealed a
significant survival benefit from adjuvant interferon treatment
regarding recurrence-free survival (RFS; P < 0.05) if MTAP
expression was observed in the primary melanoma. Patients with
STAT1-positive melanomas also tended to benefit from interferon
concerning RFS (P = 0.074) and showed a significant benefit
concerning overall survival (OS; P < 0.05). According to Cox
analysis, MTAP expression in contrast to STAT1 was an
independent positive prognostic marker for RFS and OS. In
conclusion, MTAP represents a highly promising
immunohistochemical marker for prognosis and interferon
response of patients with malignant melanoma.
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Introduction
Methylthioadenosine phosphorylase (MTAP), which is con-
stitutively expressed in most normal cells and tissues, plays
a significant role in polyamine metabolism; the housekeep-
ing enzyme catalyses the phosphorylation of methylthioade-
nosine (MTA), a by-product of polyamine synthesis (1).
Lack of MTAP activity was shown to occur in several
malignant diseases like breast cancer, endometrial cancer,
leukaemia, osteosarcoma and hepatocellular carcinoma
(2–6). Loss of MTAP activity was related to deletions in
human chromosome 9p21, encoding the tumor suppressor
genes CDKN2A and CDKN2B, MTAP, and interferon alpha
and beta and to epigenetic regulation by promoter hyper-
methylation (1,7).
In malignant melanomas, selective deletions in this chro-
mosomal region or promoter hypermethylation are known
to result in a loss of MTAP protein expression. Immuno-
histochemistry (IHC) studies revealed a significant inverse
association between MTAP protein expression and progres-
sion of melanocytic tumors, with the amount of MTAP
protein staining decreasing from benign melanocytic nevi
to metastatic melanomas (7).
In addition to its role in polyamine metabolism, MTAP
expression has significant impact on signal transducer and
activator of transcription 1 (STAT1) activity (8). STAT1 is
activated by peptide hormones, growth factors and cyto-
kines, particularly cytokines of the interferon family, and is
essential for the activation of interferon c signalling path-
ways (9). Mowen et al. (2001) postulated an association
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between MTAP activity and interferon sensitivity via the
transcription factor STAT1 which requires phosphorylation
on its serine residue (ser 727) for maximal transcriptional
activity induced by interferon c. Consistently, recent in vitro
experiments in melanoma cell lines have illustrated that
re-expression of MTAP leads to responsiveness to inter-
feron (7).
In our previous work based on a subgroup analysis of a
small cohort of patients with melanoma, we suggested that
MTAP might be a predictive marker of interferon therapy
resistance in patients with melanoma and disease progres-
sion (10). As reliable markers for the prediction of therapy
outcome of adjuvant interferon treatment are urgently
needed, in the tissue microarray study presented here, a large
cohort of patients with melanoma was analysed to evaluate
whether expression of MTAP and the downstream signal
transducer and transcription activator STAT1 are of prog-
nostic or therapeutic relevance in patients with melanoma.
Materials and methods
The medical ethical committee of the University of Regens-
burg, Germany, approved all described experiments. The
retrospective study was conducted according to the Decla-
ration of Helsinki Principles.
Tissue microarrays
Tissue microarrays (TMAs) were constructed as described
previously (11) and contained a total of 465 formalin-fixed,
paraffin-embedded human tissues from 465 different
patients: 364 (78.3%) primary malignant melanomas, 39
(8.4%) metastases and 62 (13.3%) benign nevi. In patients
with multiple subsequent neoplasms, only initial and single
primary malignant melanomas were included. H&E-stained
slides of all tumors were evaluated by two dermatohistopa-
thologists (TV, SM). Clinical follow-up data, provided by
the Central Tumour Registry Regensburg, were available
for all patients with primary malignant melanomas; for sta-
tistical analysis, only patients with a minimum follow-up
period of 6 months were considered (n = 360), i.e. four
patients with primary malignant melanoma were excluded
from further investigation owing to a shorter follow-up
period. The median follow up for all patients with malig-
nant melanoma was 51.5 months (range 6–186 months).
The University of Regensburg institutional review board
granted approval for the project. Characteristic parameters
of the TMA are summarised in Table 1 and S1.
Immunohistochemical analysis
Paraffin-embedded preparations of tissues from patients
with benign melanocytic nevi, malignant melanomas and
melanoma metastases were screened for MTAP and STAT1
protein expression by IHC as described previously (7,10,12).
In brief, tissues were deparaffinised, rehydrated and subse-
quently incubated with primary polyclonal chicken anti-
MTAP ⁄monoclonal rabbit anti-STAT1 antibody (1:1.500 ⁄
1:200) overnight at 4C. The secondary antibody (biotin-
labelled anti-chicken, 1:1.000; Jackson ImmunoResearch
Laboratories, Ltd., West Grove, PA ⁄biotin-labelled anti-rab-
bit, Zytomed Systems, Berlin, Germany) was incubated for
30 min at room temperature, followed by incubation with
streptavidin-peroxidase (Dako Cytomation GmbH, Ham-
burg, Germany) for 30 min. The following primary antibod-
ies were used: anti-MTAP (generous gift from Dr D. Carson,
University of California), anti-STAT1 (rabbit monoclonal;
Cell Signalling; 1:200; final concentration 10 lg ⁄ml) and
anti-Ki67 (rabbit monoclonal, clone MIB1; Dako; 1:10, final
concentration 5 lg ⁄ml). As an internal positive control for
MTAP IHC, normal squamous epithelium of the epidermis
was chosen; human colon carcinoma tissue served as positive
Table 1. MTAP expression analysis of melanocytic skin tumors
Melanocytic lesions (n = 461)
Cytoplasmic MTAP immunoreactivity1 Cytoplasmic STAT1 immunoreactivity2
n
analysable3
score 0
(n)
Score
1+ to 2+ (n) P*
n
analysable4
Score
0 (n)
Score
1+ to 3+ (n) P*
Total 392 75 317 <0.001 440 276 164 <0.001
Primary malignant melanomas5 297 55 242 341 194 147
Melanoma metastases 34 19 15 39 24 15
Benign nevi 61 1 60 60 58 2
MTAP, methylthioadenosine phosphorylase; STAT1, signal transducer and activator of transcription 1.
*Chi-square test; boldface indicates statistical significance.
1MTAP staining intensity (0 to 2+): 0, negative; 1+, weak positive; 2+, strong positive.
2STAT1 staining intensity (0 to 3+): 0, negative; 1+, weak positive; 2+, strong positive; 3+, very strong positive.
3Missing data because of missing values: n = 69.
4Missing data because of missing values: n = 21.
5Only initial and single primary malignant melanomas were included.
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control for STAT1 IHC. Antibody binding was visualised
using AEC solution (Dako). Tissues were counterstained
with hemalaun. A surgical pathologist (FB) and a dermatoh-
istopathologist (SM) performed a blinded evaluation of the
stained slides. According to Wild et al. (2006), cytoplasmic
MTAP staining intensity was estimated using a semiquanti-
tative three-step scoring system (0 to 2+): 0, negative; 1+,
weak positive; 2+, strong positive. Cytoplasmic STAT1 stain-
ing intensity was estimated using a semiquantitative four-
step scoring system (0 to 3+): 0, negative; 1+, weak positive;
2+, strong positive, 3+, very strong positive. In consider-
ation of the small amount of tissue of each individual tumor
on the TMA, even weak MTAP and STAT1 immunoreactiv-
ity (1+) was considered positive. The percentage of Ki-67-
positive cells of each specimen was determined as described
previously (13). High-Ki-67 labelling index was defined if at
least 5% of the tumor cells were positive.
Statistical analysis
All specimens on the TMAs were considered independently.
Regarding the patients with primary melanomas, only cases
with a minimum follow-up period of 6 months were
included. Contingency table analysis, two-sided Chi-square
and Fisher’s exact tests were used to study the statistical
association between clinicopathological and immunohisto-
chemical parameters. Retrospective overall survival (OS)
and recurrence-free survival (RFS) curves comparing
patients with or without any of the factors were calculated
using the Kaplan-Meier method, with significance evaluated
by two-sided log rank statistics. For the analysis of RFS,
patients were censored at the time of their last tumor-free
clinical follow-up appointment. For OS analysis, patients
were censored at the time of their last clinical follow-up
appointment or at their date of death not related to the
tumor. P values <0.05 were considered significant.
Statistical analyses were completed using SPSS version 15.0
(SPSS, Chicago, IL, USA). Multivariable Cox regression
models for OS and RFS were adjusted, testing the indepen-
dent prognostic relevance of MTAP and STAT1 immunore-
activity, with tumor thickness as a continuous and status of
interferon therapy as dichotomous variable. Further models
including the interaction between MTAP and interferon
therapy (respectively STAT1 and interferon therapy) were
analysed. As these analyses were exploratory in nature and
further validation of our results is hence necessary, no
adjustments for multiple testing were made in order to
avoid loss of statistical power.
Results
Immunohistochemical analysis
Using TMA technology, investigation of MTAP and STAT1
protein expression was informative in 392 (85%) of 461
and 440 (95%) of 461 cases, respectively (data were missing
for 69 and 21 cases). MTAP and STAT1 protein expression
of any intensity was detected in 317 (81%) of 392 and in
164 (37%) of 440 informative cases. Table 1 summarises
the IHC results for each tumor entity on the TMA. Com-
pared with benign nevi, expression of MTAP was signifi-
cantly reduced in malignant melanomas and melanoma
metastases (P < 0.001); in contrast, expression of STAT1
significantly increased (P < 0.001). MTAP and STAT1
immunoreactivity were not significantly associated
(P = 0.268).
Clinicopathological variables were compared relative to
MTAP and STAT1 expression (Table S1). In primary mela-
nomas, loss of MTAP expression was significantly related
to higher Clark levels (P < 0.05) and greater tumor thick-
ness (P < 0.01). Increased STAT1 expression was signifi-
cantly associated with female gender (P < 0.05) and a
tumor thickness of 1.5–4.0 mm (P < 0.05). On the TMA,
no differences in MTAP and STAT1 expression were
observed between compound and dermal nevi.
Prognostic relevance
Using univariate log rank statistics, OS and RFS were com-
pared between MTAP-positive and -negative cases, and
STAT1-positive and -negative cases (Table 2). In patients
with primary malignant melanomas, expression of MTAP
was significantly associated with OS (P < 0.01) (Fig. 1a)
and RFS (P < 0.05) (Fig. 1b), respectively. For the expres-
sion of STAT1, no significant prognostic relevance was
found regarding OS (P = 0.160) and RFS (P = 0.492).
According to a global Cox regression model without
variable selection, expression of MTAP represented an
independent positive prognostic marker for both RFS (haz-
ard ratio 0.361, 95% confidence interval 0.172–0.758,
P < 0.01; Table S2a) and OS (hazard ratio 0.554, 95% con-
fidence interval 0.319–0.962, P < 0.05; Table S2b); in con-
trast to expression of STAT1. Interferon therapy and tumor
thickness showed significant influences in both Cox
models.
Predictive relevance
To evaluate the therapeutic benefit, a subgroup analysis
was performed among the melanoma patients with a tumor
thickness of 1.5–4 mm with (low-dose interferon alpha:
three million units, administered subcutaneously three
times a week, mostly for 24 months) and without adjuvant
interferon treatment. Interferon alpha therapy is recom-
mended in an adjuvant setting for patients with melanoma
with high risk of recurrence, i.e., a minimum tumor thick-
ness of 1.5 mm without clinically detectable lymph node
metastases and after resection of lymph node metastases
corresponding to stages II to III (AJCC 2002), respectively
(http://www.ado-homepage.de/projekte/1/upload/kurzleitli-
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niemelanom20063.pdf). The upper threshold of tumor
thickness was defined at 4.0 mm as tumors with a thickness
‡4 mm are rarely observed (14), and the almost linear cor-
relation between tumor thickness and melanoma-specific
mortality rate is lost beyond 4 mm (15). This subgroup of
patients was considered to be most representative for the
majority of patients with melanoma receiving adjuvant
treatment, and therefore chosen for further analysis.
In this subgroup of R0 resected patients with a tumor
thickness of 1.5–4 mm (UICC stage IB: five patients, stage
II: 24 patients, stage III: three patients, stage IV: three
patients, missing stage: four patients), patients with MTAP-
positive primary melanomas treated with interferon had a
significantly longer RFS (P < 0.05) compared to patients
with MTAP-negative tumors (Fig. 2a) and tended to show
a longer OS (median survival 80 months versus 35 months
Table 2. Univariate analysis of clinicopathological variables relative to recurrence-free survival (RFS) and overall survival (OS) among patients with
primary malignant melanoma (n = 360)
Variable Categorisation
Tumor recurrence (RFS) Tumor-related death (OS)
n1 Events P* n1 Events P*
Age at diagnosis £60 years 176 33 0.202 178 42 0.124
>60 years 180 20 182 53
Gender Female 164 20 0.914 168 32 0.003
Male 192 33 192 63
Clark level2 I 1 0 <0.001 1 0 <0.001
II 74 2 75 8
III 106 6 106 11
IV 143 34 146 59
V 14 5 14 11
Tumor thickness <1.5 mm 206 9 <0.001 209 24 <0.001
1.5–4.0 mm 96 22 96 35
>4.0 mm 48 20 49 33
Nodal status pN0 314 42 <0.01 317 74 <0.001
pN1 11 6 11 8
pN2 6 2 6 5
pN3 4 2 4 3
Ki67 labelling index £5% 199 23 <0.05 200 48 0.205
>5% 139 27 142 41
Cytoplasmic MTAP IHC Score 0 53 11 <0.05 55 19 <0.01
Score 1+ to 2+ 240 36 242 63
Cytoplasmic STAT1 IHC Score 0 192 31 0.492 194 57 0.160
Score 1+ to 3+ 145 19 147 32
MTAP, methylthioadenosine phosphorylase; IHC, Immunohistochemistry; STAT1, signal transducer and activator of transcription 1.
*Log rank test (2-sided), boldface indicates statistical significance.
1only initial and single primary malignant melanomas were included (numbers <360 because of missing values).
2taken from Sobin LH, Wittekind CH, eds. UICC: TNM Classification of Malignant Tumours. 6th edn. New York, NY: John Wiley & Sons Inc; 2002.
(a) (b)
Figure 1. Methylthioadenosine phosphorylase (MTAP) expression is associated with prognosis of patients with melanoma. In patients with primary
malignant melanomas, expression of MTAP was significantly associated with (a) overall survival (n = 297; P < 0.01) and (b) recurrence-free survival
(n = 293; P < 0.05) as estimated by the Kaplan-Meier method.
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for MTAP-negative melanomas; P = 0.119) (Fig. 2b). There
was no significant prognostic relevance comparing patients
with MTAP-positive and -negative tumors who did not
receive interferon treatment concerning RFS (P = 0.836)
(Fig. 2c) or OS (P = 0.241) (Fig. 2d). Patients with STAT1-
positive melanomas with interferon treatment did not show
a significant benefit concerning RFS (P = 0.074) (Fig. 3a),
but showed a calculated benefit concerning OS (P < 0.05)
(Fig. 3b). There was no prognostic relevance comparing
patients with STAT1-positive and -negative tumors who
did not receive interferon treatment regarding RFS
(P = 0.203) (Fig. 3c) and OS (P = 0.512) (Fig. 3d).
Patients with melanoma, with a tumor thickness >4 mm
with and without interferon therapy did not show a signifi-
cant survival benefit concerning OS or RFS regardless of
MTAP or STAT1 immunoreactivity (data not shown).
(a)
(b)
(c)
(d)
Figure 2. Methylthioadenosine phosphorylase
(MTAP) expression is correlated with interferon
therapy response of patients with melanoma. In
patients with primary malignant melanomas (tumor
thickness: 1.5–4 mm), expression of MTAP was
significantly associated with recurrence-free survival
in patients (a) receiving adjuvant interferon
treatment (n = 34; P < 0.05) in contrast to patients
(c) without interferon treatment (n = 44; P = 0.836)
as estimated by the Kaplan-Meier method; MTAP
expression was not significantly associated with
overall survival in patients (b) with (n = 34;
P = 0.119) and (d) without interferon therapy
(n = 44; P = 0.241).
(b)
(a)
(d)
(c)
Figure 3. Signal transducer and activator of
transcription 1 (STAT1) expression and
interferon therapy response of patients with
melanoma. In patients with primary malignant
melanomas (tumor thickness: 1.5–4 mm),
expression of STAT1 was not associated with
(a) recurrence-free survival (n = 35;
P = 0.074) but significantly associated with
(b) overall survival (n = 35; P < 0.05) in
patients who received adjuvant interferon
treatment as estimated by the Kaplan-Meier
method; expression of STAT1 was not
significantly associated with (c) recurrence-
free survival (n = 54; P = 0.203) or (d) overall
survival (n = 54; P = 0.512) in patients who
did not receive interferon treatment.
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Discussion
This study clearly shows that MTAP protein expression of
primary malignant melanomas is of prognostic relevance
and predictive for adjuvant interferon therapy response in
patients with primary melanomas.
A significant inverse association between MTAP protein
expression and progression of melanocytic tumors was
recently shown by immunohistochemical TMA analysis of
tissue samples of 80 malignant melanomas, 95 melanoma
metastases and 137 benign nevi that revealed decreasing
amounts of MTAP protein staining in the progression
from benign nevi to metastatic melanomas (10). In this
former, smaller study, MTAP immunoreactivity was not
associated with prognosis regarding OS or RFS. Based on
a subgroup analysis within this study performed among
13 patients with MTAP-negative and 26 patients with
MTAP-positive melanomas with tumor recurrence,
patients with MTAP-negative melanomas with tumor
recurrence and interferon treatment showed a significantly
reduced OS compared to patients with MTAP-positive
melanomas with tumor recurrence and interferon treat-
ment (P < 0.01). In conclusion, loss of MTAP protein
expression was suggested to be a predictive marker for
interferon therapy resistance in patients with melanoma
and disease progression (10). This implicates that MTAP
inactivation might affect tumor response to interferon
therapy in patients with melanoma. To validate these data,
further quantification of MTAP expression in a larger
cohort of patients with melanoma was of particular inter-
est as reliable markers for prediction of therapy outcome
are urgently needed.
According to Mowen et al. (2001), MTAP activity and
interferon sensitivity are associated via STAT1, a signal
transducer and transcription factor downstream of MTAP,
which modulates interferon a ⁄b-induced transcription.
Reduction of MTAP activity in the cell leads to accumulation
of MTA, which acts as an inhibitor of methyltransferases.
Methylation of arginine 31 in STAT1 by protein arginine
N-methyltransferase 1 (PRMT1) was found to be an impor-
tant modification. Loss of this modification leads to
enhanced binding of protein inhibitor of activated STAT
(PIAS1) to STAT1, and, therefore to inhibition of STAT1
DNA binding activity. As STAT1 is essential for interferon
signalling pathways, loss of MTAP was expected to reduce
the cell response to interferon treatment. Based on this pos-
tulate, we analysed the expression of STAT1 for its prognos-
tic and predictive relevance in addition to MTAP expression.
In contrast to our previous study including 80 patients
with primary malignant melanomas (10), in this large TMA
study based on a total of 360 patients with melanoma with
a minimum follow-up period of 6 months, MTAP immu-
noreactivity was associated with prognosis (i.e. OS and
RFS). For expression of STAT1, however, no significant
prognostic relevance was found regarding OS (P = 0.160)
and RFS (P = 0.492) (see Table 2). Moreover, no signifi-
cant influence of STAT1 was found on RFS or OS in global
Cox regression models in contrast to MTAP. Summing up,
compared with the transcription factor STAT1, which is
located downstream of MTAP in interferon signalling
pathways in different modes of activation, MTAP represents
a promising candidate to predict individual prognoses
of patients with melanoma. Recently, Wang et al. (16)
suggested that the relative balance of pSTAT1 ⁄pSTAT3 may
be associated with melanocyte differentiation in vivo, and
pSTAT3 is a potential biomarker of melanocytic transfor-
mation and progression which is modulated by interferon
alpha dose-dependently. Accordingly, STAT3 was suggested
to be a potential target for chemoprevention of melanoma.
Considering these aspects, it would be of particular interest
to study other candidates in the Janus-activated kinase ⁄
signal transducers and activators of transcription (STAT)
pathway of interferon signalling in relation to MTAP
expression and the therapeutic impact of interferon.
Owing to the evident need of predictive markers for ther-
apy outcome, we subdivided the collective into groups with
and without adjuvant interferon treatment. In addition,
patients with primary malignant melanomas with a tumor
thickness of 1.5–4.0 mm (pT2-3) and larger than 4.0 mm
(pT4) were analysed in parallel to evaluate the predictive
impact of MTAP and STAT1 immunoreactivity regarding
responsiveness to adjuvant interferon treatment. Consistent
with the findings of Mowen et al. (2001) and our previous
observations (10), in the small but representative subgroup
of patients analysed in this retrospective study patients with
MTAP-positive melanomas with a tumor thickness of
1.5–4.0 mm had a significant benefit from interferon
treatment regarding RFS (P < 0.05) and tended to benefit
from interferon treatment regarding OS (median survival
80 months versus 35 months for MTAP-negative melano-
mas; P = 0.119), whereas patients with STAT1-positive mel-
anomas (tumor thickness of 1.5–4.0 mm) tended to benefit
from interferon treatment concerning RFS (P = 0.074) and
showed a significant benefit concerning OS (P < 0.05).
Interestingly, no predictive value was found for patients
with tumors larger than 4 mm pointing to enhanced
aggressiveness probably because of additional, yet poorly
understood molecular changes and pathways involved in
the biology of very thick primary malignant melanomas.
Compared to STAT1, a transcription factor with differ-
ent modes of activation located downstream of MTAP in
interferon signalling pathways, determination of the MTAP
immunoreactivity in primary malignant melanomas prior
to interferon treatment seems to be an appropriate tool to
pre-estimate a patient’s chance to benefit from interferon
therapy.
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Our data, supporting the previously suggested associa-
tion between MTAP activity and interferon sensitivity, may
be of particular clinical importance as biological markers
predictive for tumor response to adjuvant interferon ther-
apy have not yet been defined. Up to now, interferon alpha
is the only therapeutic agent in adjuvant treatment of
malignant melanomas showing a significant (metastasis
free) survival benefit in prospective randomised clinical tri-
als (17,18). As previously mentioned, adjuvant therapy with
interferon alpha should be recommended to all patients
with melanoma with high risk of recurrence (tumor thick-
ness >1.5 mm and ⁄or lymph node metastases) unless there
are clear contraindications. Any adjuvant treatment with
interferon may have serious side effects and reduces the
quality of life. Hence, the indications for interferon treat-
ment have to be carefully assessed. For systematic selection
of high-risk patients with melanoma with a predictable
chance to benefit from interferon therapy, immunohisto-
chemical profiling of primary malignant melanomas
responding to interferon treatment would be of major clin-
ical interest.
According to the data presented here, MTAP represents
a highly promising immunohistochemical marker to pre-
dict a patient’s prognosis and responsiveness to adjuvant
interferon treatment. Prospective clinical trials will validate
the predictive value of MTAP immunoreactivity for routine
clinical assessment of primary malignant melanomas
regarding response to interferon treatment. There is a com-
pelling rationale for new research upon targeted antitumor
therapies (19) including interferon response, especially in
adjuvant settings as recently summarised (18). Scientific
approaches that may enable practitioners to determine
which patients may benefit from interferon therapy are
essential for a patient-oriented therapy of malignant mela-
noma and indispensable from the health economic point of
view.
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